CL2011001128A1 - Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas. - Google Patents
Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas.Info
- Publication number
- CL2011001128A1 CL2011001128A1 CL2011001128A CL2011001128A CL2011001128A1 CL 2011001128 A1 CL2011001128 A1 CL 2011001128A1 CL 2011001128 A CL2011001128 A CL 2011001128A CL 2011001128 A CL2011001128 A CL 2011001128A CL 2011001128 A1 CL2011001128 A1 CL 2011001128A1
- Authority
- CL
- Chile
- Prior art keywords
- chain
- acid molecule
- ribonucleic acid
- inhibiting
- comprised
- Prior art date
Links
- 229920002477 rna polymer Polymers 0.000 title abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 208000001435 Thromboembolism Diseases 0.000 title abstract 2
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940012413 factor vii Drugs 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108010023321 Factor VII Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Abstract
Molécula de ácido ribonucleico de doble cadena capaz de inhibir la expresión del gen del factor VII; secuencia de ácido nucleico que codifica una cadena sentido y/o una cadena antisentido que están comprendidas en dicha molécula de ácido ribonucleico; composición farmacéutica y su uso para tratar enfermedades tromboembólicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08169301 | 2008-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011001128A1 true CL2011001128A1 (es) | 2012-03-16 |
Family
ID=41510498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001128A CL2011001128A1 (es) | 2008-11-17 | 2011-05-16 | Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100124547A1 (es) |
EP (1) | EP2358876A1 (es) |
JP (1) | JP2012508569A (es) |
KR (1) | KR20110069887A (es) |
CN (1) | CN102216457A (es) |
AR (1) | AR074124A1 (es) |
AU (1) | AU2009315665A1 (es) |
BR (1) | BRPI0921096A8 (es) |
CA (1) | CA2743249A1 (es) |
CL (1) | CL2011001128A1 (es) |
IL (1) | IL212570A0 (es) |
MX (1) | MX2011004909A (es) |
PE (1) | PE20120115A1 (es) |
RU (1) | RU2011124146A (es) |
SG (1) | SG171737A1 (es) |
TW (1) | TW201021833A (es) |
WO (1) | WO2010055041A1 (es) |
ZA (1) | ZA201103424B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2705316A1 (en) * | 2007-11-09 | 2009-05-14 | Isis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
US9512471B2 (en) * | 2010-06-30 | 2016-12-06 | Diacarta Inc | Methods and kits for detecting human papillomavirus |
JP6336755B2 (ja) | 2010-11-12 | 2018-06-06 | ザ ジェネラル ホスピタル コーポレイション | ポリコームに関連する非コードrna |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
AU2011349464B2 (en) * | 2010-12-20 | 2016-07-07 | The General Hospital Corporation | Polycomb-associated non-coding RNAS |
CA2822462A1 (en) * | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
KR102534909B1 (ko) * | 2011-11-18 | 2023-05-30 | 알닐람 파마슈티칼스 인코포레이티드 | 변형된 RNAi 제제 |
EP2850188A4 (en) | 2012-05-16 | 2016-01-20 | Rana Therapeutics Inc | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE MULTIGENIC FAMILY OF HEMOGLOBIN |
AU2013262699A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating ATP2A2 expression |
CN104583402A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
US10059941B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
SG11201407486PA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating utrn expression |
EP3212824A4 (en) | 2014-10-30 | 2018-08-08 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
CA2984636A1 (en) * | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4134066A (en) * | 1977-03-24 | 1979-01-09 | International Business Machines Corporation | Wafer indexing system using a grid pattern and coding and orientation marks in each grid cell |
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
ATE113059T1 (de) * | 1987-06-24 | 1994-11-15 | Florey Howard Inst | Nukleosid-derivate. |
US4924624A (en) * | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5216141A (en) * | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5591722A (en) * | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264562A (en) * | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
EP0942000B1 (en) * | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5177198A (en) * | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5587470A (en) * | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5587361A (en) * | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5459255A (en) * | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5506351A (en) * | 1992-07-23 | 1996-04-09 | Isis Pharmaceuticals | Process for the preparation of 2'-O-alkyl guanosine and related compounds |
US5212295A (en) * | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5670633A (en) * | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5321131A (en) * | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) * | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5218105A (en) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5608046A (en) * | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5602240A (en) * | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5610289A (en) * | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US6262241B1 (en) * | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
US5214134A (en) * | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5594121A (en) * | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5359044A (en) * | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
EP0577558A2 (de) * | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
GB9304618D0 (en) * | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
WO1994022891A1 (en) * | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
US5571902A (en) * | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
US5519134A (en) * | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) * | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5554746A (en) * | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
US5597909A (en) * | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US6166197A (en) * | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
US6172209B1 (en) * | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6271358B1 (en) * | 1998-07-27 | 2001-08-07 | Isis Pharmaceuticals, Inc. | RNA targeted 2′-modified oligonucleotides that are conformationally preorganized |
DK3604537T3 (da) * | 2003-06-13 | 2022-02-28 | Alnylam Europe Ag | Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme |
CA2707042A1 (en) * | 2007-12-10 | 2009-06-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor vii gene |
-
2009
- 2009-11-10 PE PE2011000979A patent/PE20120115A1/es not_active Application Discontinuation
- 2009-11-10 CN CN2009801459337A patent/CN102216457A/zh active Pending
- 2009-11-10 WO PCT/EP2009/064940 patent/WO2010055041A1/en active Application Filing
- 2009-11-10 BR BRPI0921096A patent/BRPI0921096A8/pt not_active IP Right Cessation
- 2009-11-10 RU RU2011124146/10A patent/RU2011124146A/ru not_active Application Discontinuation
- 2009-11-10 JP JP2011535995A patent/JP2012508569A/ja not_active Withdrawn
- 2009-11-10 KR KR1020117011054A patent/KR20110069887A/ko not_active Application Discontinuation
- 2009-11-10 EP EP09752172A patent/EP2358876A1/en not_active Withdrawn
- 2009-11-10 SG SG2011035276A patent/SG171737A1/en unknown
- 2009-11-10 AU AU2009315665A patent/AU2009315665A1/en not_active Abandoned
- 2009-11-10 MX MX2011004909A patent/MX2011004909A/es not_active Application Discontinuation
- 2009-11-10 CA CA2743249A patent/CA2743249A1/en not_active Abandoned
- 2009-11-12 US US12/616,828 patent/US20100124547A1/en not_active Abandoned
- 2009-11-13 AR ARP090104411A patent/AR074124A1/es not_active Application Discontinuation
- 2009-11-16 TW TW098138880A patent/TW201021833A/zh unknown
-
2011
- 2011-04-28 IL IL212570A patent/IL212570A0/en unknown
- 2011-05-10 ZA ZA2011/03424A patent/ZA201103424B/en unknown
- 2011-05-16 CL CL2011001128A patent/CL2011001128A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0921096A2 (pt) | 2015-08-25 |
CA2743249A1 (en) | 2010-05-20 |
TW201021833A (en) | 2010-06-16 |
MX2011004909A (es) | 2011-05-30 |
JP2012508569A (ja) | 2012-04-12 |
US20100124547A1 (en) | 2010-05-20 |
AU2009315665A1 (en) | 2010-05-20 |
RU2011124146A (ru) | 2012-12-27 |
SG171737A1 (en) | 2011-07-28 |
AR074124A1 (es) | 2010-12-22 |
ZA201103424B (en) | 2012-01-25 |
BRPI0921096A8 (pt) | 2016-05-10 |
CN102216457A (zh) | 2011-10-12 |
IL212570A0 (en) | 2011-06-30 |
WO2010055041A1 (en) | 2010-05-20 |
EP2358876A1 (en) | 2011-08-24 |
KR20110069887A (ko) | 2011-06-23 |
PE20120115A1 (es) | 2012-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011001128A1 (es) | Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas. | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
AR114031A2 (es) | Moléculas de unión a 4-1bb | |
CL2008000857A1 (es) | Acido ribonucleico de doble cadena para inhibir la expresion de un gen e6ap humano en una celula; vector y celula; composicion farmaceutica que lo comprende; y su uso para tratar trastornos asociados con el virus de papiloma humano. | |
BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
CL2011002765A1 (es) | Anticuerpo anti-factor de crecimiento nervioso (ngf) con estabilidad in vivo aumentada; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; kit; y su uso para tratar una enfermedad o afeccion relacionada con ngf. | |
CL2013000669A1 (es) | Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie. | |
CO6470854A2 (es) | Variantes de celulasa con expresión, actividad y/o estabilidad mejoradas, y uso de las mismas | |
CR20160117A (es) | Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos | |
ECSP12011685A (es) | Inmunoconjugados dirigidos | |
BR112014025020A2 (pt) | composições e métodos para inibição da expressão do gene alas1 | |
EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
UY35703A (es) | Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos | |
CL2011000642A1 (es) | Unidad de dosificacion que comprende 25 a 400 mg del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico; kit farmaceutico que comprende la unidad de dosificacion; y su uso para el tratamiento de fibrosis quistica. | |
CL2008001674A1 (es) | Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento. | |
AR078516A1 (es) | Moleculas de union a dll-4 (ligando 4 de tipo delta) | |
AR079883A1 (es) | Plantas tolerantes a herbicidas inhibidores de las hppd | |
CO6410314A2 (es) | Proteínas de unión a il-17 | |
BR112012015740A2 (pt) | anticorpos de anti-flt3 e metodos de uso dos mesmos | |
CO6300844A2 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
CL2008002444A1 (es) | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. | |
EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
CL2013001975A1 (es) | Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta. | |
CL2011002611A1 (es) | Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17. | |
CO2018012513A2 (es) | Anticuerpos |